Eli Lilly and Company (NYSE:LLY) is one of the 13 best blue-chip stocks to buy, according to analysts. On June 30, RBC ...

Eli Lilly is grabbing investor attention thanks to sharp earnings and revenue growth projections, though its Zacks Rank ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly stock currently trades below its 50-week average, offering a strong entry point despite continued dominance in ...

Citi stated that as the obesity space evolves from injectables to convenient orals, such as orforglipron, the emergence of a ...

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...

FILE PHOTO: Vials of Eli Lilly's Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and weight loss, are seen in a fridge at a health clinic in Hyderabad, India, April 14, 2025.

As Her Spectacular Career Winds Down, a Look at the Excellence of Lilly King It’s official: Lilly King is retiring. The three-time Olympian and breaststroke legend announced in a May 31 ...

Deals: AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 ...

Estimates for Eli Lilly’s 2025 earnings have declined from $23.06 to $21.95 per share in the past 60 days, and estimates for 2026 earnings have declined from $31.15 to $30.91 over the same ...

Earlier this week, Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion. The acquisition will add Verve’s pipeline of gene ...